ライフサイエンスコーパス: p

1 ltration in patients on peritoneal dialysis (PD).

2 nagement protocol for pancreatoduodenectomy (PD).

3 can be augmented by protein supplementation (PS).

4 s to centralize care for patients undergoing PD.

5 verall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively).

6 en by enhanced C uptake during spring (129%, P = 0.001) and fall (124%, P = 0.001), respectively, whi

7 Rituximab (odds ratio = 9.52; P = 0.001), and high-dose steroids (odds ratio = 5.05; P

8 socioeconomic status (SES) at time of birth (P = 0.001), but not parental age nor maternal gestationa

9 ing spring (129%, P = 0.001) and fall (124%, P = 0.001), respectively, which was consistent across ye

10 not related to a stented site (59% vs. 26%, p = 0.001).

11 o experience complications (odds ratio 1.51, P = 0.002) and longer hospital stays (+12%, P = 0.006).

12 o, 3.06; 95% confidence interval, 1.52-6.16; P = 0.002).

13 ase (p = 0.014) and ischaemic heart disease (p = 0.003), possibly due to competing causes of death ov

14 gitation moderate or higher (19.4% vs. 6.8%; p = 0.003).

15 ndently associated with increased mortality (P = 0.003; odds ratio, 1.254; 95% confidence interval, 1

16 the WNT16 and RSPO3 loci and fracture risk (P = 0.004 and 4.0 x 10-4, respectively).

17 8%-15.6%; adjusted means $26,604 vs $24,263; P = 0.005), 12.4% longer length of stay (95% CI 2.3%-23.

18 f the anti-inflammatory mediator arginase-1 (P = 0.005), and a sustained reduction in skin redness (P

19 OPN (0.787, P < 0.001), and OPN-HpAb (0.801, P = 0.006), as well as one-biomarker of PGI/II (0.735, P

20 P = 0.002) and longer hospital stays (+12%, P = 0.006).

21 her serum vitamin D3 levels after treatment (P = 0.007) demonstrated increased skin expression of the

22 cases to 9.7 cases per 10,000 patient-days (P = 0.008).

23 reduced in the stable LTx group (24 +/- 8%, P = 0.009), but not in the BOS TxP group (53 +/- 10%, P

24 , and high-dose steroids (odds ratio = 5.05; P = 0.01) retained significance in multivariable analysi

25 nd disease free survival (DFS) (p = 0.00001; p = 0.01, respectively).

26 ity dose trends for all circulatory disease (p = 0.014) and ischaemic heart disease (p = 0.003), poss

27 2.3%-23.5%; adjusted means 5.9 vs 5.2 days; P = 0.015), more complications (odds ratio 1.36; 95% CI

28 hose in refractory ventricular fibrillation (p = 0.017).

29 treated patients, respectively, by month 12 (P = 0.018) and 2.3% (8/353) and 4.5% by month 24 (P = 0.

30 95% CI 1.08-2.29; adjusted rates 10% vs 6%; P = 0.018), and no difference in discharge destination (

31 of alterations in a multivariable analysis (P = 0.019).

32 on of cumulative 6-year GPP by warming (29%, P = 0.02) and eCO2 (26%, P = 0.07) was primarily driven

33 , and a sustained reduction in skin redness (P = 0.02), correlating with significant expression of ge

34 95% CI 1.04-1.78; adjusted rates 20% vs 16%; P = 0.023), more readmissions (odds ratio 1.57; 95% CI 1

35 creatinine (HR: 0.62; 95% CI: 0.40 to 0.95; p = 0.03), and AKI (HR: 0.68; 95% CI: 0.58 to 0.81; p <

36 se postoperative BCVA (0.06 vs. 0.03 logMAR, P = 0.039).

37 .73; 95% confidence interval (CI) 1.03-2.91; P = 0.03].

38 r thromboses (4.4% vs 1.3% tx alone, 0% pre; P = 0.04).

39 ation (risk ratio, 0.50 [95% CI, 0.25-1.01]; p = 0.05; low-quality evidence); no reduction in toleran

40 PP by warming (29%, P = 0.02) and eCO2 (26%, P = 0.07) was primarily driven by enhanced C uptake duri

41 ] in infants = 7,118 and in adults = 11,510, P = 0.070; V1V2 median MFIs of 512 [infants] and 804 [ad

42 and no difference in discharge destination (P = 0.11).

43 .018) and 2.3% (8/353) and 4.5% by month 24 (P = 0.145).

44 ps (6.4 +/- 2.3 mm Hg vs. 5.8 +/- 2.7 mm Hg; p = 0.17), whereas the ViR group had more frequent post-

45 ce between the groups (FFT: 35% vs LFT: 29%, P = 0.290), neither regarding the overall population, no

46 no evidence of an interaction (p = 0.329 and p = 0.291 for CKD and CVD, respectively).

47 6 +/- 9.3 U/L vs 7 hours, 24.8 +/- 14.6 U/L, P = 0.298).

48 effects, with no evidence of an interaction (p = 0.329 and p = 0.291 for CKD and CVD, respectively).

49 P = 0.636) or rectal (FFT: 44% vs LFT: 35%, P = 0.330) cancer subgroups.

50 dian MFIs of 512 [infants] and 804 [adults], P = 0.50), whereas infants immunized with the MF59/SF-2

51 pital mortality was similar (12.4% vs 10.3%; p = 0.635).

52 ion, nor in the colon (FFT: 23% vs LFT: 19%, P = 0.636) or rectal (FFT: 44% vs LFT: 35%, P = 0.330) c

53 150 mL/min (hazards ratio, 1.00 [0.60-1.69]; p = 0.68).

54 in postoperative anterior chamber reaction (P = 0.7) or LPI area (P = 0.9) were noted between the 2

55 feeds (risk ratio, 0.94 [95% CI, 0.62-1.42]; p = 0.77; low-quality evidence), and no change in the du

56 confirmed in 4 (2.1%) versus 6 (3.2%) cases (p = 0.79).

57 8, P = 0.890; and visual field loss, -0.019, P = 0.819).

58 ction margins (AHR, 0.9; 95% CI, 0.4 to 2.2; P = 0.86).

59 zed mean differences of visual acuity 0.008, P = 0.890; and visual field loss, -0.019, P = 0.819).

60 rior chamber reaction (P = 0.7) or LPI area (P = 0.9) were noted between the 2 groups.

61 d controls (C/TTCTG: gamma(2) value = 0.014; p = 0.904).

62 ), but not in the BOS TxP group (53 +/- 10%, P = 0.97).

63 ding Pd(0)/Pd(II), Pd(II)/Pd(IV), and Pd(II)/Pd(0).

64 ation via various redox manifolds, including Pd(0)/Pd(II), Pd(II)/Pd(IV), and Pd(II)/Pd(0).

65 001) and development of carcinoma (1% vs 3%; P= 0.008).

66 d similar rates of cyst growth (19% vs. 20%; P= 0.95) and lower rates of cross-over to resection (5%

67 F-FDOPA uptake (in caudate: age </=50 years, p=0.0002; all other age ranges, p<0.0001; in putamen: al

68 ly correlated with baseline hs-TnT (r=-0.27, P=0.001).

69 tiapine-ER (15 [30%] of 50; estimated 31.3%; p=0.0021), but not at other timepoints.

70 users spent more time in target (68% vs 61%; p=0.0034) and less time hyperglycaemic (27% vs 32%; p=0.

71 ty by 28% (P=0.020), 25% (P=0.009), and 18% (P=0.004), respectively, over a total of 20 years of foll

72 benefit (OR 0.95 per extra year, 0.92-0.98; p=0.004).

73 c factor for recurrence (hazard ratio, 1.78; P=0.005).

74 d all-cause mortality by 28% (P=0.020), 25% (P=0.009), and 18% (P=0.004), respectively, over a total

75 ally significant (0.2 [SD 1.1] vs 0.1 [1.1], p=0.010) difference between the two groups in change fro

76 0-1) at day 90 (OR 7.6, 95% CI 1.6 to 37.2, p=0.010).

77 I at months 12 to 15 (P<0.001) and 30 to 33 (P=0.011).

78 02+/-2.32 vs. 0.56+/-1.39 ng per milliliter, P=0.02).

79 cular death, and all-cause mortality by 28% (P=0.020), 25% (P=0.009), and 18% (P=0.004), respectively

80 relative risk (RR)=1.14 (95% CI: 1.02, 1.27; p=0.024) for a lag of 2 wk; the estimated risk increased

81 4) and less time hyperglycaemic (27% vs 32%; p=0.0279) than did pregnant control participants, with c

82 ), and trough levels increased to 218 ng/ml (P=0.03), above the 90th percentile for the 5-mg dose in

83 ime curve further increased to 6045 ng h/ml (P=0.03), and trough levels increased to 218 ng/ml (P=0.0

84 d the risk of coronary heart disease by 27% (P=0.033) and major adverse cardiovascular events by 25%

85 major adverse cardiovascular events by 25% (P=0.037) during the initial trial phase and the risk of

86 We found a significant interaction (p=0.051) between type of fractionation and treatment eff

87 rol) and time spent hypoglycaemic (3% vs 4%; p=0.10).

88 sion after first shock (from 12.3% to 13.8%; P=0.13).

89 perature range (288.15-318.15)K at pressure, p=0.1MPa.

90 ts occurred in 2.0% in fTRA and 2.9% in TFA (P=0.40).

91 CI, 6.7-15.7, versus 8.7%; 95% CI, 4.2-16.7; P=0.684).

92 I -7.0 to 4.3; hazard ratio 0.96, 0.68-1.35, p=0.81).

93 higher than in LOD (32%) or controls (15%) (P = .0001).

94 antly correlated with shorter PFS (P = .006, P = .0001, P = .002, and P = .0001, respectively).

95 rter PFS (P = .006, P = .0001, P = .002, and P = .0001, respectively).

96 d serum Phleum pratense-specific IgE levels (P = .001) compared with those in the control arm.

97 lated with shorter PFS (P = .006, P = .0001, P = .002, and P = .0001, respectively).

98 an with IFN (HR, 0.72; 95% CI, 0.58 to 0.89; P = .003).

99 all RT (central, S3, T3, I3, and N3 sectors, P = .004-.024) and the thickness of the ONL (T6 and I6 s

100 the disability scale; 95% CI, 0.06 to 0.35; P = .006).

101 mpared with controls (group effect, F = 8.0; P = .006).

102 ncreased pain interference (difference, 2.0; P = .006).

103 e significantly correlated with shorter PFS (P = .006, P = .0001, P = .002, and P = .0001, respective

104 the thickness of the ONL (T6 and I6 sectors, P = .007 and P = .009) and photoreceptor layer (N6 secto

105 y correlated with FEV1 %predicted (r = 0.43; P = .008).

106 NET complexes and both microbiota diversity (P = .009) and dominance of Haemophilus species operation

107 of the ONL (T6 and I6 sectors, P = .007 and P = .009) and photoreceptor layer (N6 sector, P = .038).

108 justed odds ratio, 4.24; 95% CI, 1.36-13.25; P = .01) were associated with a mole-prone phenotype.

109 ophilus species operational taxonomic units (P = .01).

110 % per year]; HR, 0.65; 95% CI, 0.45 to 0.94; P = .02) by the dietary intervention.

111 E group (treatment main effect: F1,68 = 5.4, P = .02, d = 0.50, and Delta = 2.4 [95% CI, 0.4-4.5]).

112 -power fields (AHR, 2.5; 95% CI, 1.1 to 6.0; P = .03), whereas there was no significant effect of neg

113 ion had decreased fatigue (difference, -1.4; P = .035), whereas patients who underwent autologous rec

114 = .009) and photoreceptor layer (N6 sector, P = .038).

115 h less >/= grade 3 pneumonitis (7.9% v 3.5%, P = .039) and a reduced risk in adjusted analyses (odds

116 hazard ratio [AHR], 2.3; 95% CI, 1.0 to 5.1; P = .04) and > 5 mitoses per 50 high-power fields (AHR,

117 7%]; relative risk, 2.87; 95% CI, 1.01-8.17; P = .04) but not with heparin plus GPI (0 vs 3 [0.3%]; P

118 s (odds ratio, 0.41; 95% CI, 0.171 to 0.986; P = .046).

119 nowledge of CD (aOR = 2.4; 95% CI = 1.0-5.8; P = .047), and exposure to all 3 at-risk housing types (

120 thatched roof) (aOR = 2.5; 95% CI = 1.0-6.4; P = .048) were associated with positive diagnosis.

121 djusted effect, 1.47; 95% CI, -0.01 to 2.91; P = .05).

122 ence in procedure duration was seen overall (P = .060).

123 GA, it was 35 minutes (IQR, 20-74 minutes) (P = .098).

124 and PTL and support further investigation of PD-1 blockade in these diseases.

125 significantly increased the efficacy of anti-PD-1 checkpoint blockade.

126 that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating an

127 Pdcd1 (PD-1) disruption augmented CAR T cell mediated killing o

128 ecutive function (differences of 0.6-0.7 SD; P=1.2x10(-3)-2.4x10(-4)).

129 with CD, 12 subjects with moderate to severe PS, 10 subjects with both AD and CD, and 10 HC with no h

130 5% in the conventional fractionation group ( P = .148).

131 copy number alteration levels (rho = -0.484, P = 2 x 10-10).

132 (-6)), and rs7700147, an intergenic variant (P=2.93 x 10(-5)).

133 ut not with heparin plus GPI (0 vs 3 [0.3%]; P = .30).

134 identified as a risk factor of BPD (OR 1.8, p = 5.3 x 10(-5)), independently of the robust antenatal

135 RNA-seq data, but proportions were similar (P = .73) across all genus-level taxonomic categories.

136 d: rs10791286, an intronic variant in OPCML (P=9.89 x 10(-6)), and rs7700147, an intergenic variant (

137 jugative DNA transfer in E. coli and trigger P. aeruginosa T6SS killing, but not pilus production.

138 Laboratory strains of Escherichia coli and P. aeruginosa were killed by a process of condensing int

139 e-wide association study with a dimensional, PD/AG-related anxiety phenotype based on the Agoraphobia

140 Moreover, PES/AG membranes demonstrated higher antifouling and ten

141 Mean values for PD and CAL in the two hypertriglyceridemic groups were s

142 sociated with multiple non-motor symptoms in PD and have important clinical consequences, including t

143 r-thiophene (TTT) and alternating phenylene (P) and thiophene (T) units as PTP and TPT.

144 ex (mSBI), plaque index (PI), probing depth (PD), and clinical attachment level (CAL).

145 ment (MCI), patients with Parkinson disease (PD), and young and older healthy volunteers.

146 We find that the repulsion exponent p approximately 6.5 provides an excellent fit for the ex

147 ome species with prunasin, tyramine and beta-p-arbutin, may be limited in food applications.

148 heterozygous mutant PEX6 allele (c.2578C>T [p.Arg860Trp]) was overrepresented due to allelic express

149 PD arterioles exhibited particular upregulation of the c

150 f site-specific incorporation of a clickable p-azido-L-phenylalanine to Uox and strain-promoted azide

151 tes a photoreactive, non-natural amino acid, p-benzoyl-l-phenylalanine, into various positions of the

152 surface methodology to identify the optimal Pd-Bi-Te catalyst stoichiometry.

153 ing a stabilized attenuating mutation in the P/C gene (C(Delta170)).

154 f cytochrome c by replacing tyrosine 48 with p-carboxy-methyl-l-phenylalanine (pCMF).

155 We identified 89,790 incident PD cases and 118,095 comparable controls aged > 65 years

156 This Review summarizes the advancements in Pd-catalyzed C(sp(3))-H activation via various redox man

157 Utilizing a recently discovered precatalyst, Pd-catalyzed Suzuki-Miyaura and Buchwald-Hartwig reactio

158 the most electron donating functional group (p-(CH3CH2)2NPh-MoS2) is the most efficient catalyst for

159 A novel 3D Co-Nx |P-complex-doped carbon grown on flexible exfoliated grap

160 btained as compared to the recently reported p-cresol sensor.

161 rotein VP3 folds into a globular protruding (P) domain, exposed on the virion surface.

162 the medical management of Parkinson disease (PD) during Ramadan.

163 PR2] (R: Cy (1), (i)Pr (2)) with discrete Ge-P exo bonds.

164 f the Erythrocyte binding antigen family and P. falciparum reticulocyte binding-like families.

165 n agent-based stochastic simulation model of P. falciparum transmission was used to investigate the s

166 After inoculation of P. flocculosa, the tripartite interaction was monitored

167 rtality, and HCC in a dose-dependent manner (P for trend <0.0001, <0.0001, and 0.009, respectively).

168 to 6 years (P(U,LPS) < 0.001; P(PI) = 0.051; P(FOXP3) < 0.001).

169 pressure, driven by a corresponding shift in p FS.

170 ding the N gene (pre-N) or between the N and P genes (N-P) of rHPIV1 bearing a stabilized attenuating

171 bipolar device at the different flow rates (P > .05 for all outcomes).

172 of the stratified variables were found (all p > 0.05).

173 Here we discover that NAD(P)H oxidase 4 (NOX4), an enzyme known to catalyse the ox

174 nzyme known to catalyse the oxidation of NAD(P)H, is upregulated when p16 is inactivated by looking a

175 The p.H67R variant reduced nuclear entry of p50 and showed d

176 via various redox manifolds, including Pd(0)/Pd(II), Pd(II)/Pd(IV), and Pd(II)/Pd(0).

177 Herein, we report a silver-free Pd(II)-catalyzed C(sp(3))-H arylation of saturated bicyc

178 , including Pd(0)/Pd(II), Pd(II)/Pd(IV), and Pd(II)/Pd(0).

179 ous redox manifolds, including Pd(0)/Pd(II), Pd(II)/Pd(IV), and Pd(II)/Pd(0).

180 In addition to reaction with O2, cis-[Pd(IPr)2(eta(2)-O2)] reacts at low temperature with H2O

181 2O in methanol/ether solution to form trans-[Pd(IPr)2(OH)(OOH)].

182 duced dyskinesia (LID) in Parkinson disease (PD) is an unmet need.

183 ox manifolds, including Pd(0)/Pd(II), Pd(II)/Pd(IV), and Pd(II)/Pd(0).

184 bits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer i

185 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 i

186 7) by quantitative immunofluorescence in the PD-L1 index tissue microarray.

187 s a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and progr

188 mor cells in vitro and enhanced clearance of PD-L1+ tumor xenografts in vivo.

189 epithelial cells with surface expression of PD-L1, E-cadherin, CD24, and VEGFR2 rapidly formed tumor

190 .001) and elevated Cr at Day 90 (HR = 2.56, P < .0001) were associated with increased risk of DCGF;

191 iring IBx had far greater impact (HR = 13.8, P < .0001).

192 Early AR (HR = 1.77, P < .001) and elevated Cr at Day 90 (HR = 2.56, P < .000

193 adjusted odds ratio, 9.08; 95% CI, 4.0-23.7; P < .001) and increased variability of nevus dermoscopic

194 r of TTA, 0.06 days; 95% CI, 0.03-0.08 days; P < .001) but was not associated with increased risk of

195 the disability scale; 95% CI, 0.57 to 1.20; P < .001) than MI (0.20 points on the disability scale;

196 llary RNFL was 5.7 mum (95% CI, 4.3-7.1 mum; P < .001) thinner than in children whose mothers had not

197 ickness (P < .001), decreasing scan quality (P < .001), and increasing age (P < .03).

198 ales (13698 [24.4%]) to receive medications (P < .001), as were non-Hispanic black (105 [14.8%]) and

199 differences with decreasing RNFL thickness (P < .001), decreasing scan quality (P < .001), and incre

200 adoran origin (aOR = 6.2; 95% CI = 2.8-13.5; P < .001), prior knowledge of CD (aOR = 2.4; 95% CI = 1.

201 s having high BPE (71% vs 29%, respectively; P < .001).

202 the GO arm than in the No-GO arm (26% v 49%; P < .001).

203 follow-up, compared with untreated controls (P < .001).

204 3%; LDV/SOF, 1.4%; untreated controls, 2.5%; P < .001).

205 th non-Hispanic white (17119 [23.1%]) youth (P < .001).

206 ; males: 3.4% [IQR, 0.4%-32.9%] of baseline; P < .001).

207 tivity in at-risk than control participants (p < .006).

208 scan quality (P < .001), and increasing age (P < .03).

209 correlated with peak colonic gas (r = 0.57; P < .05).

210 d-diastolic (161 +/- 36 ml to 122 +/- 30 ml; p < 0.001) and left atrial volumes (106 +/- 36 ml to 69

211 r of PGI/II (0.735, P < 0.001), HpAb (0.737, P < 0.001) and OPN(0.713, P < 0.001), respectively.

212 3), and AKI (HR: 0.68; 95% CI: 0.58 to 0.81; p < 0.001) compared with warfarin.

213 BMI (P < 0.001), maternal prepregnancy BMI (P < 0.001), and lower family socioeconomic status (SES)

214 -HpAb (0.786, P < 0.001), PGI/II-OPN (0.787, P < 0.001), and OPN-HpAb (0.801, P = 0.006), as well as

215 ement after surgery (-0.50 vs. -0.32 logMAR, P < 0.001), and slightly worse postoperative BCVA (0.06

216 95% confidence interval [CI]: 0.66 to 0.89; p < 0.001), doubling of serum creatinine (HR: 0.62; 95%

217 of the minimum angle of resolution (logMAR), P < 0.001), greater mean BCVA improvement after surgery

218 , as well as one-biomarker of PGI/II (0.735, P < 0.001), HpAb (0.737, P < 0.001) and OPN(0.713, P < 0

219 In contrast, higher paternal BMI (P < 0.001), maternal prepregnancy BMI (P < 0.001), and l

220 mensional combination of PGI/II-HpAb (0.786, P < 0.001), PGI/II-OPN (0.787, P < 0.001), and OPN-HpAb

221 001), HpAb (0.737, P < 0.001) and OPN(0.713, P < 0.001), respectively.

222 fraction (45.6 +/- 17.4% vs. 55.3 +/- 11.1%; p < 0.001).

223 vaptan (-2.4 +/- 2.1 kg vs. -0.9 +/- 1.8 kg; p < 0.001).

224 hnical and 95% of nontechnical performances (P < 0.001).

225 FIs of 23,926 [infants] and 1,538 [adults]; P < 0.001).

226 rial volumes (106 +/- 36 ml to 69 +/- 24 ml; p < 0.001).

227 21 in medium and 1.25 in low volume centers (P < 0.001).

228 n extubation readiness test within 10 hours (p < 0.001).

229 Cellular and secreted levels of OEA and PEA (P < 0.001-0.001) were increased in response to inflammat

230 FIs of 15,509 [infants] and 2,290 [adults], P < 0.001; V1V2 median FIs of 23,926 [infants] and 1,538

231 of 176.7 +/- 152.4 s of arc after training (p < 0.01).

232 marked cytoplasmic to nuclear shift in COPD (P < 0.01).

233 ts treated at GR and at MSKCC, respectively (P < 0.01).

234 Daytime MBS were significantly larger (all P < 0.04) by up to 8.5-fold in +DD compared to -DD subje

235 is impaired in aged hearts during ischemia (P < 0.05 vs. young hearts).

236 were dramatically increased out to 28 days (P < 0.05).

237 neutrophils compared to healthy neutrophils (P < 0.05).

238 ver, higher on the BSD than on the DSD (both P < 0.05).

239 expressed regions with >|2| fold change and p </= 0.05.

240 nificantly higher than those of the H group (P <0.001).

241 and PISA scores among the study groups with P <0.05.

242 iation between %5 mC and LTL in females (all ps < 0.01), but not in males.

243 rates of cross-over to resection (5% vs 11%; P< 0.0001) and development of carcinoma (1% vs 3%; P= 0.

244 ding (all age ranges in caudate and putamen, p<0.0001) and (18)F-FDOPA uptake (in caudate: age </=50

245 nts (36.4%), and white male patients (30.2%, P<0.0001).

246 atients during SWS and 461 (61%) during STM (p<0.0001).

247 tched nonperforation survivors without a CP (P<0.0001).

248 anges, p<0.0001; in putamen: all age ranges, p<0.0001).

249 </=50 years, p=0.0002; all other age ranges, p<0.0001; in putamen: all age ranges, p<0.0001).

250 dependently predicted MI at months 12 to 15 (P<0.001) and 30 to 33 (P=0.011).

251 success (OR 0.95 per extra year, 0.93-0.98; p<0.001) and clinical benefit (OR 0.95 per extra year, 0

252 with full hematologic recovery (34% vs. 16%, P<0.001) and with respect to complete remission with ful

253 ere larger for men than women (heterogeneity P<0.001), but RRs for serious liver complications appear

254 tial shockable rhythms (from 58.9% to 69.2%; P<0.001), there was no difference in unadjusted rate of

255 4% at 8 years after rejection, respectively; P<0.001).

256 ard ratio 0.62 [95% CI 0.47-0.80]; one-sided p<0.001).

257 ncomplete hematologic recovery (44% vs. 25%, P<0.001).

258 934 for DCEMRI (p<0.68) and 0.852 for DCECT (p<0.001).

259 tudinal strain at 1 year (hazard ratio=0.29; P<0.001).

260 ions appeared higher in women (heterogeneity P<0.001).

261 ht ventricular end-systolic volume in AF-TR (P<0.001).

262 o, 1.16; 95% confidence interval, 1.08-1.25; P<0.001).

263 o, 0.82; 95% confidence interval, 0.75-0.90; P<0.001).

264 n-6 fatty acid contents increased linearly (p<0.05) by raising the substitution levels of rice with

265 s were significantly lower than that of BLS (p<0.05), while significant decreases in the setback and

266 d muscle more effectively compared to oxyMb (P<0.05).

267 84 for DCEMRI+HB phase vs. 0.934 for DCEMRI (p<0.68) and 0.852 for DCECT (p<0.001).

268 interest in parts of objects' and rs2898883 (P<6.8 x 10(-9)), which resides within the sixth intron o

269 Using a stringent significance threshold (P<7.1 x 10(-9)), GWAS in the AGP revealed an association

270 polydimethylsiloxane (PDMS), or polystyrene (PS) macromonomer.

271 ensile stress (by 31%) when compared to pure PES membranes.

272 de-major histocompatibility complex class I (p-MHC I) proteins displayed by antigen-presenting cells.

273 exchange of charge between the host [Co6Te8(P(n)Pr3)6][C60]3 and the intercalant TCNE.

274 more confident signal assignment than 1D (31)P NMR, although currently the ubiquitous use of this nov

275 gene (pre-N) or between the N and P genes (N-P) of rHPIV1 bearing a stabilized attenuating mutation i

276 ed positive associations between exposure to p,p'-DDE and BMI z-score (beta=0.13 BMI z-score (95% CI:

277 ore (95% CI: 0.01, 0.25) per log increase of p,p'-DDE).

278 Parkinson's disease (PD) patients experience loss of normal motor function (h

279 With the ratio P/Pcr of the peak power of an ultrashort laser pulse, P,

280 d from age 4.5 to 6 years (P(U,LPS) < 0.001; P(PI) = 0.051; P(FOXP3) < 0.001).

281 ted to attenuation of the reflection loss of p-polarized light and multiple reflections within the wa

282 ngenital myasthenic syndrome in one patient (p.Pro210Leu), to severe neurodevelopmental delay with br

283 The structure of a QuiC1 enzyme from P. putida reveals that the protein is a fusion of two di

284 CPO_Abeta17-21 P reduced Abeta-related pathology coupled with cognitive

285 It is defined as the area under the P rofile of S hannon D ifference (PSD).

286 4E, phosphorylated 4E-binding protein 1, and p-S6 ribosomal protein.

287 neurodevelopmental delay with brain atrophy (p.Ser94Arg) and extend the clinical outcomes to a more s

288 To understand the adhesive secretions of P. shermani, its components were chemically analysed by

289 we compared the functional contributions of P. simiae genes to growth in 90 distinct in vitro condit

290 Cellular imaging using a phospho-specific p-T153/Y155 antibody showed that phosphorylated TDP-43 w

291 y recruited to the nucleoli, suggesting that p-T153/Y155 regulates a previously unappreciated functio

292 ribed which are conjugatively linked through p-ter-phenyl (PPP), ter-thiophene (TTT) and alternating

293 the peak power of an ultrashort laser pulse, P, to the critical power of self-focusing, Pcr, playing

294 sk factors across ethnic/racial populations (p-trends < 0.01).

295 Arsenic is a promising p-type dopant; however, reproducible doping with high co

296 using an Ag-coated microfluidic channel on a p-type silicon nanowire (SiNW) array measured by a multi

297 n ex vivo decreased from age 4.5 to 6 years (P(U,LPS) < 0.001; P(PI) = 0.051; P(FOXP3) < 0.001).

298 availability, for instance increasing plant P uptake more with a pulsed water supply compared to a r

299 re severe spectrum with infantile lethality (p.Val112Glu).

300 Most P. vivax studies must therefore rely on patient samples,

301 neurons while exhibiting milder cell loss in PD, we aimed to define the electrophysiological properti

302 ed single unit activity in ten patients with PD who performed repetitive feet or hand movements while

303 which reveal a large and unexpected shift of p* with pressure, driven by a corresponding shift in p F

304 R models for benzene, toluene, ethylbenzene, p-xylene, m-xylene, o-xylene (BTEX), and total BTEX usin

305 The level of nitrogen (N), phosphorus (P), zinc (Zn), iron (Fe), and copper (Cu) in the fruit p